

**Sotrovimab**

* **EUA granted:** 5/26/21, last updated 12/15/21
* **What is it?** An engineered human monoclonal antibody that neutralizes SARS-CoV-2 and other sarbecoviruses. [Anticipated](https://www.biorxiv.org/content/10.1101/2021.12.14.472630v1.full.pdf) to retain activity against omicron VOC.
	+ COMET-ICE Trial reported 79% reduction in hospitalization at day 29.
* **Availability?**
	+ Extremely limited availability
	+ As of 1/25/22: NIH COVID-19 Treatment Guidelines has recommended after Paxlovidin order of preference
	+ Currently distributed by the state based on incidence rates/hospitalization.
* **Key Points in EUA:**
	+ Adults and pediatrics (12yo age and older ≥ 40kg) with mild to moderate COVID-19
		- Positive test
		- Within 10 days of symptom onset

AND

* + - High risk for progression to severe COVID-19 including hospitalization or death
			* See [CDC information](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html) for information on additional factors and medical conditions associated with an increased risk for progression of COVID-19
* **Per Kootenai Health Scarce Resource Committee:**
	+ With limited supplies, recommend prioritized use for HIGHEST RISK patients
	+ Immunocompromised individuals not expected to mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection due to their underlying conditions, regardless of vaccine status
	+ *or*
	+ Unvaccinated individuals at the highest risk of severe disease (anyone aged ≥75 years or anyone aged ≥65 years with additional risk factors)
* **Not authorized for use in patients:**
	+ Hospitalized for COVID-19
	+ Requiring oxygen due to COVID-19 or increase in baseline oxygen
* **Dosage & Administration:**
	+ 500mg vials; must be diluted in 50-100mL 0.9% sodium chloride or D5W and administered over 30-min
	+ Monitor patients for at least 1 hour after end of infusion.
* **Adverse reactions:**
	+ Pre-medications may be ordered as well as medications for treatment of adverse reactions available on order set.
	+ Rare hypersensitivity reactions have been reported up to 24 hours after infusion. fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (e.g., presyncope, syncope), dizziness, and diaphoresis.
	+ Slow or stop infusion and administer appropriate medications if an infusion related reaction occur.
* **Healthcare providers must document the following** **(must be checked on order form):**
	+ Patient has been given “[Fact Sheet for Patients, Parents, and Caregivers](https://www.fda.gov/media/149533/download)”
	+ Patient informed of alternatives prior to receiving sotrovimab and that it is an unapproved drug authorized for use under this EUA (provider & patient have signed consent & copy faxed to pharmacy
	+ Patient verification/consent form must be signed by patient and placed in medical record/chart.

References:

* COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/> . Accessed [Jan 4th 2022]
* Emergency Use Authorization for SOTROVIMAB. [Fact Sheet for patients, parents, and caregivers] The U.S. Food and Drug Administration (FDA). <https://www.fda.gov/media/149534/download>
* Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Providers [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html%20Accessed%20Jan%205th%202022)html Accessed Jan 5th 2022